Nebulised heparin as a treatment for COVID-19 : Scientific rationale and a call for randomised evidence
-
Van Haren, Frank M. P. (Intensive Care Unit. Canberra Hospital)
;
Page, Clive (Sackler Institute of Pulmonary Pharmacology. King's College London) ;
Laffey, John (Galway University Hospital) ;
Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Camprubí-Rimblas, Marta (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Nunes, Quentin (Institute of Systems. Molecular and Integrative Biology. University of Liverpool) ;
Smith, Roger (St Vincent's Hospital (Sydney)) ;
Shute, Janis (School of Pharmacy and Biomedical Science. University of Portsmouth) ;
Carroll, Mary (National Infection Service. Public Health England) ;
Tree, Julia (National Infection Service. Public Health England) ;
Carroll, Miles (National Infection Service. Public Health England) ;
Singh, Dave (Medicines Evaluation Unit. University of Manchester) ;
Wilkinson, Tom (Department of Respiratory Medicine. University of Southampton) ;
Dixon, Barry (St Vincent's Hospital (Sydney)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
